Zaidman Irina, Mohamad Hadhud, Shalom Lidor, Ben Arush Myriam, Even-Or Ehud, Averbuch Dina, Zilkha Amir, Braun Jacques, Mandel Asaf, Kleid David, Attias Ori, Ben-Ari Josef, Brooks Rebecca, Gefen Aharon, Stepensky Polina
Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Pediatr Blood Cancer. 2022 Mar;69(3):e29549. doi: 10.1002/pbc.29549. Epub 2021 Dec 30.
Although hematopoietic stem cell transplantation (HSCT) is the only curative option for some children with malignant and nonmalignant disorders, the procedure itself carries a high risk of complications. A proportion of children undergoing HSCT develop severe transplant-related complications requiring hospitalization in the pediatric intensive care unit (PICU).
A retrospective cohort study included 793 children with malignant and nonmalignant diseases that underwent 963 HSCTs in two large pediatric hospitals over 15 years. Ninety-one patients needed 105 (11%) PICU admissions. The objective of the study was to analyze the risk factors associated with morbidity and mortality in children post HSCT who were admitted to the PICU.
Survival rate of a single PICU hospitalization was 43%. Long-term survival rate (classified as 1 year and 3 years) was 29.1% and 14.9% among PICU hospitalized patients compared with 74.6% and 53.3% among patients who had undergone HSCT and did not require PICU hospitalization. Factors found to have a significant negative association with PICU survival were respiratory failure as indication for PICU admission, neutropenia, graft-versus-host disease, mechanical ventilation, inotropic support, need for dialysis, and multiple-organ failure (MOF) with more than one systemic intensive intervention. The strongest prognostic factors associated with mortality were MOF (p < .001) and the need for inotropic support (p = .004).
Neutropenia was found to be negatively associated with survival, suggesting non-engraftment and late engraftment are important risk factors for HSCT patients hospitalized in PICU. MOF and inotropic support were found to be the main negatively associated predictive factors with survival.
尽管造血干细胞移植(HSCT)是一些患有恶性和非恶性疾病的儿童唯一的治愈选择,但该手术本身具有很高的并发症风险。一部分接受HSCT的儿童会出现严重的移植相关并发症,需要入住儿科重症监护病房(PICU)。
一项回顾性队列研究纳入了793例患有恶性和非恶性疾病的儿童,这些儿童在15年期间于两家大型儿科医院接受了963次HSCT。91例患者需要105次(11%)入住PICU。本研究的目的是分析入住PICU的HSCT术后儿童发病和死亡的相关危险因素。
单次入住PICU的生存率为43%。在入住PICU的患者中,长期生存率(分类为1年和3年)分别为29.1%和14.9%,而在接受HSCT且不需要入住PICU的患者中,长期生存率分别为74.6%和53.3%。发现与PICU生存有显著负相关的因素包括作为入住PICU指征的呼吸衰竭、中性粒细胞减少、移植物抗宿主病、机械通气、血管活性药物支持、透析需求以及需要多次全身强化干预的多器官功能衰竭(MOF)。与死亡率相关的最强预后因素是MOF(p <.001)和血管活性药物支持需求(p = 0.004)。
发现中性粒细胞减少与生存呈负相关,提示植入失败和延迟植入是入住PICU的HSCT患者的重要危险因素。发现MOF和血管活性药物支持是与生存负相关的主要预测因素。